Signaturefd LLC Has $1.11 Million Stock Position in argenx SE (NASDAQ:ARGX)

Signaturefd LLC increased its stake in shares of argenx SE (NASDAQ:ARGX) by 10.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,804 shares of the company’s stock after purchasing an additional 167 shares during the quarter. Signaturefd LLC’s holdings in argenx were worth $1,109,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. FMR LLC raised its position in argenx by 35.9% during the third quarter. FMR LLC now owns 4,793,472 shares of the company’s stock valued at $2,598,445,000 after acquiring an additional 1,265,486 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of argenx by 0.4% in the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock valued at $1,343,797,000 after purchasing an additional 10,975 shares during the period. Wellington Management Group LLP raised its position in shares of argenx by 13.0% in the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock valued at $261,470,000 after purchasing an additional 55,617 shares during the period. Alkeon Capital Management LLC raised its position in shares of argenx by 15.0% in the third quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company’s stock valued at $187,018,000 after purchasing an additional 45,000 shares during the period. Finally, Jennison Associates LLC raised its position in shares of argenx by 27.0% in the fourth quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after purchasing an additional 64,183 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $611.18 on Wednesday. The company’s fifty day moving average is $636.83 and its 200-day moving average is $598.22. The company has a market capitalization of $37.14 billion, a PE ratio of -694.52 and a beta of 0.59. argenx SE has a 52 week low of $349.86 and a 52 week high of $678.21.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million for the quarter, compared to analyst estimates of $678.52 million. On average, analysts forecast that argenx SE will post 3.13 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft raised shares of argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, March 12th. Wells Fargo & Company boosted their target price on shares of argenx from $723.00 to $741.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Guggenheim boosted their target price on shares of argenx from $775.00 to $1,100.00 and gave the stock a “buy” rating in a research report on Monday, March 10th. Piper Sandler boosted their target price on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. Finally, Citigroup reiterated an “outperform” rating on shares of argenx in a research note on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, argenx has a consensus rating of “Moderate Buy” and an average price target of $687.00.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.